BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 25712457)

  • 1. Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL).
    Chihara D; Asano N; Ohmachi K; Nishikori M; Okamoto M; Sawa M; Sakai R; Okoshi Y; Tsukamoto N; Yakushijin Y; Nakamura S; Kinoshita T; Ogura M; Suzuki R
    Ann Oncol; 2015 May; 26(5):966-973. PubMed ID: 25712457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors of central nervous system relapse in mantle cell lymphoma.
    Conconi A; Franceschetti S; Lobetti-Bodoni C; Stathis A; Margiotta-Casaluci G; Ramponi A; Mazzucchelli L; Bertoni F; Ghielmini M; Gaidano G; Cavalli F; Zucca E
    Leuk Lymphoma; 2013 Sep; 54(9):1908-14. PubMed ID: 23339449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
    Hoster E; Rosenwald A; Berger F; Bernd HW; Hartmann S; Loddenkemper C; Barth TF; Brousse N; Pileri S; Rymkiewicz G; Kodet R; Stilgenbauer S; Forstpointner R; Thieblemont C; Hallek M; Coiffier B; Vehling-Kaiser U; Bouabdallah R; Kanz L; Pfreundschuh M; Schmidt C; Ribrag V; Hiddemann W; Unterhalt M; Kluin-Nelemans JC; Hermine O; Dreyling MH; Klapper W
    J Clin Oncol; 2016 Apr; 34(12):1386-94. PubMed ID: 26926679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mantle Cell Lymphoma Involving Skin: A Clinicopathologic Study of 37 Cases.
    Kim DH; Medeiros LJ; Aung PP; Young KH; Miranda RN; Ok CY
    Am J Surg Pathol; 2019 Oct; 43(10):1421-1428. PubMed ID: 31219818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network.
    Cheah CY; George A; Giné E; Chiappella A; Kluin-Nelemans HC; Jurczak W; Krawczyk K; Mocikova H; Klener P; Salek D; Walewski J; Szymczyk M; Smolej L; Auer RL; Ritchie DS; Arcaini L; Williams ME; Dreyling M; Seymour JF;
    Ann Oncol; 2013 Aug; 24(8):2119-23. PubMed ID: 23616279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).
    Dietrich S; Boumendil A; Finel H; Avivi I; Volin L; Cornelissen J; Jarosinska RJ; Schmid C; Finke J; Stevens WB; Schouten HC; Kaufmann M; Sebban C; Trneny M; Kobbe G; Fornecker LM; Schetelig J; Kanfer E; Heinicke T; Pfreundschuh M; Diez-Martin JL; Bordessoule D; Robinson S; Dreger P
    Ann Oncol; 2014 May; 25(5):1053-8. PubMed ID: 24585719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.
    Greenwell IB; Staton AD; Lee MJ; Switchenko JM; Saxe DF; Maly JJ; Blum KA; Grover NS; Mathews SP; Gordon MJ; Danilov AV; Epperla N; Fenske TS; Hamadani M; Park SI; Flowers CR; Cohen JB
    Cancer; 2018 Jun; 124(11):2306-2315. PubMed ID: 29579328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mantle cell lymphoma with central nervous system involvement: frequency and clinical features.
    Gill S; Herbert KE; Prince HM; Wolf MM; Wirth A; Ryan G; Carney DA; Ritchie DS; Davies JM; Seymour JF
    Br J Haematol; 2009 Oct; 147(1):83-8. PubMed ID: 19694718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.
    Rusconi C; Cheah CY; Eyre TA; Tucker D; Klener P; Giné E; Crucitti L; Muzi C; Iadecola S; Infante G; Bernard S; Auer RL; Pagani C; Duglosz-Danecka M; Mocikova H; van Meerten T; Cencini E; Marin-Niebla A; Williams ME; Angelillo P; Nicoli P; Arcari A; Morello L; Mannina D; Vitagliano O; Sartori R; Chiappella A; Sciarra R; Stefani PM; Dreyling M; Seymour JF; Visco C
    Blood; 2022 Oct; 140(17):1907-1916. PubMed ID: 35789260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central nervous system involvement by mantle cell lymphoma.
    McLaughlin N; Wang Y; Witzig T; Villasboas J; Habermann T; Inwards D; Bennani N; Thanarajasingam G; Nowakowski G; Porrata L; Thompson C; Micallef I; Johnston P; Ansell S; Paludo J
    Leuk Lymphoma; 2023 Feb; 64(2):371-377. PubMed ID: 36416595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central nervous system involvement in mantle cell lymphoma.
    Ferrer A; Bosch F; Villamor N; Rozman M; Graus F; Gutiérrez G; Mercadal S; Campo E; Rozman C; López-Guillermo A; Montserrat E
    Ann Oncol; 2008 Jan; 19(1):135-41. PubMed ID: 17962207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma.
    Arkenau HT; Chong G; Cunningham D; Watkins D; Agarwal R; Sirohi B; Trumper M; Norman A; Wotherspoon A; Horwich A
    Ann Oncol; 2007 Mar; 18(3):541-5. PubMed ID: 17164228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simplified MIPI-B prognostic stratification method can predict the outcome well-retrospective analysis of clinical characteristics and management of newly-diagnosed mantle cell lymphoma patients from China.
    He JS; Chen X; Wei GQ; Sun J; Zheng WY; Shi JM; Wu WJ; Zhao Y; Zheng GF; Huang H; Cai Z
    Medicine (Baltimore); 2019 Jan; 98(1):e13741. PubMed ID: 30608386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma.
    Räty R; Franssila K; Joensuu H; Teerenhovi L; Elonen E
    Eur J Haematol; 2002 Jul; 69(1):11-20. PubMed ID: 12270057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central nervous system relapse in a patient with mantle cell lymphoma in continuous clinical and molecular remission at six years since autografting.
    Ladetto M; Sametti S; Astolfi M; Corradini P; Ricca I; Drandi D; Pileri A; Tarella C
    Leuk Lymphoma; 2001 Feb; 40(5-6):679-82. PubMed ID: 11426542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central nervous system involvement in T-cell lymphoma: A single center experience.
    Gurion R; Mehta N; Migliacci JC; Zelenetz A; Moskowitz A; Lunning M; Moskowitz C; Hamlin P; Horwitz S
    Acta Oncol; 2016 May; 55(5):561-6. PubMed ID: 27046135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SOX11-negative Mantle Cell Lymphoma: Clinicopathologic and Prognostic Features of 75 Patients.
    Xu J; Wang L; Li J; Saksena A; Wang SA; Shen J; Hu Z; Lin P; Tang G; Yin CC; Wang M; Medeiros LJ; Li S
    Am J Surg Pathol; 2019 May; 43(5):710-716. PubMed ID: 30768440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
    Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
    Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.